Precision Biotech Taiwan

Precision Biotech Taiwan Corp. is a clinical-stage biotechnology company headquartered in Taipei, Taiwan, specializing in the development of advanced immune cell therapies. Founded in 2017, the company focuses on Natural Killer (NK) and NKT cell technologies for the treatment of solid tumors and hematological malignancies. Its lead candidate, PB101, is an autologous NK/NKT cell therapy currently in Phase 2 clinical trials, while PB103 is an allogeneic "off-the-shelf" NK cell product in Phase 1/2 development. Precision Biotech utilizes its proprietary PB-NK expansion platform and maintains GMP-compliant manufacturing facilities to ensure high-purity and high-activity cell production. The company is actively expanding its international presence through strategic partnerships in Southeast Asia and the establishment of an international headquarters in Hong Kong.